IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)

IDH2 mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation

cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • dexamethasone injection

Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) (clinicaltrials.gov)

P3, N=132, Recruiting, Ono Pharmaceutical Co. Ltd | Not yet recruiting --> Recruiting

1 day ago

Enrollment open

Rituxan (rituximab) • temozolomide • Velexbru (tirabrutinib)

Celestimo: A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma (clinicaltrials.gov)

P3, N=478, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Jan 2026 --> May 2026

1 day ago

Trial primary completion date

CD20 (Membrane Spanning 4-Domains A1)

Rituxan (rituximab) • lenalidomide • Lunsumio (mosunetuzumab-axgb)

BRAWM: Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia (clinicaltrials.gov)

P2, N=63, Active, not recruiting, Sunnybrook Health Sciences Centre | Trial primary completion date: Dec 2024 --> Dec 2025

2 days ago

Trial primary completion date

Rituxan (rituximab) • Calquence (acalabrutinib) • bendamustine

REDUCE-PMR-2: Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse (clinicaltrials.gov)

P3, N=174, Active, not recruiting, Sint Maartenskliniek | Recruiting --> Active, not recruiting

2 days ago

Enrollment closed

Rituxan (rituximab) • Truxima (rituximab-abbs)

Beyond R-CHOP: The rise of antibody-drug conjugates in DLBCL. (PubMed, Blood Rev)

Recently, ADCs have expanded the DLBCL therapeutic landscape, with the approvals of CD79b-targeted polatuzumab vedotin and CD19-directed loncastuximab tesirine for R/R and even frontline disease. However, the clinical application of ADCs is accompanied by challenges, including the management of characteristic toxicities, understanding and overcoming mechanisms of resistance. This review systematically synthesizes the mechanisms of action, updated clinical evidence, toxicity profiles, and resistance mechanisms of ADCs in DLBCL, while also discusses management strategies and provides perspectives on future directions.

2 days ago

Review • Journal

TNFRSF8 (TNF Receptor Superfamily Member 8) • CD79B (CD79b Molecule) • CD22 (CD22 Molecule)

Rituxan (rituximab) • Zynlonta (loncastuximab tesirine-lpyl) • Polivy (polatuzumab vedotin-piiq)

REDUCE-PMR-1: Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed (clinicaltrials.gov)

P3, N=114, Completed, Sint Maartenskliniek | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025

3 days ago

Trial completion • Trial completion date

Rituxan (rituximab) • Truxima (rituximab-abbs)

GLOBRYTE: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (clinicaltrials.gov)

P3, N=182, Recruiting, Hoffmann-La Roche | Trial completion date: Sep 2027 --> Mar 2028 | Trial primary completion date: Feb 2027 --> Aug 2027

3 days ago

Trial completion date • Trial primary completion date

CCND1 (Cyclin D1)

Chr t(11;14)

Rituxan (rituximab) • lenalidomide • Gazyva (obinutuzumab) • bendamustine • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) (clinicaltrials.gov)

P1/2, N=93, Completed, Memorial Sloan Kettering Cancer Center | Recruiting --> Completed | Trial completion date: Dec 2026 --> Jan 2026 | Trial primary completion date: Dec 2026 --> Jan 2026

4 days ago

Trial completion • Trial completion date • Trial primary completion date

Imbruvica (ibrutinib) • Rituxan (rituximab) • Matulane (procarbazine hydrochloride)

Have Fixed-Duration (FD) Regimens Delivered on Their Promise in Chronic Lymphocytic Leukemia and What Is the Future of FD Regimens? A Narrative Review. (PubMed, Adv Ther)

Successful fixed-duration regimens in CLL should achieve deep remission (i.e., undetectable minimal residual disease), sustain long-term progression-free survival, decrease the burden of treatment-related adverse events, and allow for re-treatment with minimal risk of drug resistance. Although fixed-duration treatment represents a positive step forward for most patients with CLL/SLL, the currently approved regimens often fall short in patients at high risk of progression. Continued research and development of next-generation drugs is essential to enhance efficacy and safety, ultimately improving outcomes in all patients with CLL/SLL.

4 days ago

Review • Journal • IO biomarker

TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)

IGH mutation

Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)